Executive Summary
EDG-15400 is a small molecule cardiac sarcomere modulator with an undisclosed target intended for future development in heart failure with preserved ejection fraction (HFpEF).
EDG-15400
Undisclosed cardiac sarcomeric target · Small molecule
Target: Undisclosed cardiac sarcomeric target
Full NameUndisclosed cardiac sarcomeric target
PathwayCardiac sarcomere function
Mechanism of Action[Pres '26 S5]
TypeCardiac sarcomere modulator
DescriptionUndisclosed mechanism targeting cardiac sarcomeric proteins
DifferentiationPart of Edgewise's muscle-focused platform with expertise in sarcomere biology
Indications: Heart Failure with Preserved Ejection Fraction (HFpEF)
Target Biology[Pres '26 S5]
The cardiac sarcomere is the basic contractile unit of heart muscle. EDG-15400 targets an undisclosed protein within the sarcomere to potentially improve cardiac function in heart failure with preserved ejection fraction.
Clinical Data
Phase 1 study in healthy adults[Pres '26 S4]
Phase 1 Ongoing n=Healthy adultsInvestment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| Edgewise's muscle biology expertise could translate to novel HFpEF approach | Company's successful development of sarcomere modulators in other indications | Low |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Very early stage asset with undisclosed mechanism in competitive HFpEF space | No clinical data available and target/mechanism undisclosed | — |
Key Debates
| Question | Bull View | Bear View | Resolution Catalyst |
|---|---|---|---|
| Can Edgewise's sarcomere expertise translate to HFpEF success? | Muscle biology platform provides unique insights for cardiac applications | HFpEF is fundamentally different from muscular dystrophies | Phase 1 safety data and Phase 2 efficacy signals |
Market Opportunity
Unmet Need: Heart failure with preserved ejection fraction represents a significant unmet medical need
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| Phase 1 EDG-15400 healthy volunteer data | H1 2026 | medium | Safety and tolerability profile in healthy volunteers | — |
| EDG-15400 Phase 2 initiation in HFpEF | H2 2026 | high | Trial design and patient population selection | — |
| EDG-15400 Phase 2 data in HFpEF | H1 2027 | critical | Efficacy signals and safety profile in HFpEF patients | — |
| Phase 1 healthy volunteer data | H1 2026 | medium | Safety, tolerability, pharmacokinetics, cardiac effects | — |
| Phase 2 initiation in HFpEF | H1 2027 | medium | Patient population, primary endpoints, differentiation vs existing HFpEF therapies | — |